Piper Sandler Issues Positive Forecast for KORU Medical Systems (NASDAQ:KRMD) Stock Price

KORU Medical Systems (NASDAQ:KRMD) had its price target boosted by Piper Sandler from $3.00 to $3.50 in a research report released on Thursday,Benzinga reports. Piper Sandler currently has an overweight rating on the stock.

Separately, B. Riley began coverage on shares of KORU Medical Systems in a report on Thursday, July 25th. They issued a “buy” rating and a $4.00 target price for the company.

KORU Medical Systems Price Performance

Shares of NASDAQ:KRMD traded up $0.10 on Thursday, reaching $3.18. 89,967 shares of the company were exchanged, compared to its average volume of 114,646. The company has a 50-day moving average of $2.65 and a 200-day moving average of $2.47. The company has a current ratio of 3.77, a quick ratio of 3.27 and a debt-to-equity ratio of 0.01. The firm has a market cap of $145.80 million, a price-to-earnings ratio of -12.48 and a beta of 0.41. KORU Medical Systems has a 1-year low of $1.98 and a 1-year high of $3.40.

Institutional Trading of KORU Medical Systems

Several institutional investors and hedge funds have recently made changes to their positions in KRMD. Aaron Wealth Advisors LLC purchased a new stake in KORU Medical Systems during the 2nd quarter worth about $28,000. Allspring Global Investments Holdings LLC acquired a new stake in shares of KORU Medical Systems during the 2nd quarter worth about $28,000. Legato Capital Management LLC purchased a new stake in shares of KORU Medical Systems during the second quarter worth about $35,000. Virtu Financial LLC acquired a new position in shares of KORU Medical Systems in the first quarter valued at approximately $63,000. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new stake in KORU Medical Systems during the second quarter worth approximately $107,000. 58.60% of the stock is currently owned by hedge funds and other institutional investors.

About KORU Medical Systems

KORU Medical Systems, Inc develops and manufactures medical devices and supplies in the United States and internationally. It offers the freedom infusion systems to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy, and paroxysmal nocturnal hemoglobinuria.